Viewing nowCombinationDuvimet ER Tablets 0.25/50/500 mg
Metformin Hydrochloride 500mg · Lobeglitazone Sulfate 0.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.

MFDS item code 202301432 · Approved 2023.05.02 · Insurance code 643309350
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication assists adult patients with type 2 diabetes in managing their blood sugar by combining Rosiglitazone, Sitagliptin, and Metformin. The effectiveness can be enhanced when accompanying dietary and exercise therapies. It effectively manages blood sugar levels and contributes to the prevention of diabetes-related complications. It is used to improve blood sugar control in patients.
For antidiabetic therapy, the recommended dose of this medicine is lobeglitazone sulfate 0.5 mg and sitagliptin 100 mg; the dose of extended-release metformin hydrochloride should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. This medicine is generally administered once daily with the evening meal, and the dose is adjusted gradually to reduce gastrointestinal adverse reactions associated with metformin. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 0.5/100/1000 mg extended-release tablet once daily. Patients taking this medicine 0.25/50/500 mg, 0.25/50/750 mg, or 0.25/50/1000 mg extended-release tablets should take 2 tablets together once daily. If adequate glycemic control cannot be achieved with metformin and sitagliptin, the starting dose of this medicine should be lobeglitazone sulfate 0.5 mg, sitagliptin 100mg, and the dose of metformin hydrochloride currently being taken, or an appropriate dose therapeutically equivalent to it. For patients switching from combination therapy with lobeglitazone, sitagliptin, and metformin to this medicine, the dose of this medicine should be the existing dose of each component. No dose adjustment is necessary in patients with mild renal impairment [estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], this medicine may be used by adjusting the metformin hydrochloride dose if it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. Renal function should be monitored closely every 3- 6 months. If creatinine clearance or estimated glomerular filtration rate decreases to below 45ml/min or 45ml/min/1.73m2, respectively, administration of this medicine should be discontinued immediately.
This medication should not be used in patients with compromised cardiac function, as it may worsen symptoms of heart failure; careful monitoring by a physician is needed. If signs of heart failure appear, consult a doctor immediately and get evaluated through necessary tests. It is also recommended not to initiate this medication in severely symptomatic heart failure patients. This medication may cause fluid retention, leading to edema or heart failure symptoms, thus patients should periodically monitor these symptoms. Allergic reactions may occur, and if symptoms such as rash, hives, or difficulty breathing appear, discontinue use immediately and inform healthcare personnel. There is a risk of serious pancreatic diseases, such as pancreatitis; thus, if symptoms like abdominal pain, nausea, or vomiting occur, seek medical attention promptly. This medication can rarely cause a serious metabolic disorder called lactic acidosis; if symptoms like sudden fatigue, muscle pain, difficulty breathing, or abdominal pain arise, consult your healthcare provider immediately. Patients with renal function impairment should not use this medication and should have regular kidney function tests. Caution is also required in patients with liver dysfunction, and the medication may be discontinued if liver test results are abnormal. During therapy, any weight gain or edema should be reported to a physician, and it is crucial to combine appropriate exercise with a dietary regimen. This medication carries a risk of hypoglycemia, requiring caution when skipping meals or engaging in vigorous exercise, and immediate action is necessary if hypoglycemic symptoms occur. Pregnant women or those planning to become pregnant should consult a physician before use, while premenopausal women should use adequate contraceptive methods during treatment due to the risk of pregnancy. If one's physical condition is poor due to surgery or severe infections, temporary discontinuation of this medication is recommended, and it may be restarted upon recovery as advised by a doctor. This medication may interact with other drugs; thus, if you are taking any other medications, it is essential to inform your physician or pharmacist. Regular testing of blood sugar, liver function, and kidney function should be done during treatment, and any adverse symptoms should be reported to healthcare personnel immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is advisable to maintain the storage temperature between 1°C and 30°C.
Light blue, bilaterally convex, oval-shaped extended-release film-coated tablet
Bottle package - 30 tablets/bottle, bottle package - 6 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 500mg · Lobeglitazone Sulfate 0.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Lobeglitazone Sulfate 0.5mg +1 more
Tablet · Prescription medication · Combination
JongKundang Co., Ltd.
CombinationMetformin Hydrochloride 750mg · Lobeglitazone Sulfate 0.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Lobeglitazone Sulfate 0.25mg +1 more
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.